Cormorant Pharmaceuticals
http://www.cormorantpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cormorant Pharmaceuticals
Salvia BioElectronics Receives FDA Breakthrough Designation For Neurostimulator To Treat Chronic Migraine
The Dutch start-up said it will work with the FDA to accelerate the development of its neurostimulator for treating chronic migraine. There are no approved implantable devices on the market for treating chronic migraine.
Biopharma Quarterly Dealmaking Statistics, Q3 2016
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Deals Shaping the Medical Industry, August 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.
Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks
With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice